Pub Date : 2009-04-01DOI: 10.1016/S1872-115X(09)00009-7
{"title":"Copyright text/Publication info.","authors":"","doi":"10.1016/S1872-115X(09)00009-7","DOIUrl":"https://doi.org/10.1016/S1872-115X(09)00009-7","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(09)00009-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137341080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-12-01DOI: 10.1016/j.uct.2008.11.001
Matthew D. Galsky , Guru Sonpavde , Ranjit Kapil , Mark T. Fleming , G. Varuni Kondagunta , Thomas E. Hutson , Cora Sternberg
Based on a better understanding of the pathogenesis of renal carcinoma, the last 5 years has witnessed a rapid transition of novel agents from the bench to the bedside. Multiple new drugs have already been approved for standard use including sunitinib, sorafenib, and temsirolimus with additional agents including everolimus, bevacizumab, and pazopanib under review by the regulatory agencies. This review will highlight the clinical data, which support the use of these novel agents and highlight current approaches exploring combination therapy.
{"title":"Development of novel agents and combinations for renal carcinoma","authors":"Matthew D. Galsky , Guru Sonpavde , Ranjit Kapil , Mark T. Fleming , G. Varuni Kondagunta , Thomas E. Hutson , Cora Sternberg","doi":"10.1016/j.uct.2008.11.001","DOIUrl":"10.1016/j.uct.2008.11.001","url":null,"abstract":"<div><p><span><span>Based on a better understanding of the pathogenesis of renal carcinoma, the last 5 years has witnessed a rapid transition of novel agents from the bench to the bedside. Multiple new </span>drugs<span> have already been approved for standard use including sunitinib, </span></span>sorafenib<span><span>, and temsirolimus with additional agents including </span>everolimus<span>, bevacizumab<span>, and pazopanib under review by the regulatory agencies. This review will highlight the clinical data, which support the use of these novel agents and highlight current approaches exploring combination therapy.</span></span></span></p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2008.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55739388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-12-01DOI: 10.1016/S1872-115X(08)00021-2
{"title":"Copyright text/Publication info.","authors":"","doi":"10.1016/S1872-115X(08)00021-2","DOIUrl":"https://doi.org/10.1016/S1872-115X(08)00021-2","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(08)00021-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137340782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-12-01DOI: 10.1016/S1872-115X(08)00024-8
{"title":"Biological Abbreviations","authors":"","doi":"10.1016/S1872-115X(08)00024-8","DOIUrl":"https://doi.org/10.1016/S1872-115X(08)00024-8","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(08)00024-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137340783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-12-01DOI: 10.1016/S1872-115X(08)00025-X
{"title":"NSC-numbers","authors":"","doi":"10.1016/S1872-115X(08)00025-X","DOIUrl":"https://doi.org/10.1016/S1872-115X(08)00025-X","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(08)00025-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137340784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-12-01DOI: 10.1016/j.uct.2008.10.001
G. Varuni Kondagunta , Guru Sonpavde , Matthew D. Galsky , Mark T. Fleming , Thomas E. Hutson , Cora N. Sternberg
Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.
{"title":"Novel treatment options for refractory germ cell tumors","authors":"G. Varuni Kondagunta , Guru Sonpavde , Matthew D. Galsky , Mark T. Fleming , Thomas E. Hutson , Cora N. Sternberg","doi":"10.1016/j.uct.2008.10.001","DOIUrl":"10.1016/j.uct.2008.10.001","url":null,"abstract":"<div><p>Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2008.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55739165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-12-01DOI: 10.1016/S1872-115X(08)00023-6
{"title":"Abbreviations of chemotherapeutic combinations","authors":"","doi":"10.1016/S1872-115X(08)00023-6","DOIUrl":"https://doi.org/10.1016/S1872-115X(08)00023-6","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(08)00023-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137340785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-12-01DOI: 10.1016/j.uct.2008.06.001
Keith Flaherty , Keiran S.M. Smalley
The standard treatments for metastatic melanoma have not evolved in the past 30 years. It has been a decade since the emergence of high-dose interferon in the adjuvant setting: a therapy with significant limitations in both efficacy and tolerability. The conventional therapies that have proven useful for other cancers have been exhausted with regard to their exploration in melanoma and novel approaches are required. The identification of somatic genetic alterations that activate the MAP kinase and PI3 kinase pathways has provided a foothold for the investigation of signal transduction inhibitors that counter them. Melanoma is more complex than some of the cancers with early success in the application of signal transduction inhibitors, such as chronic phase chronic myelogenous leukemia or gastrointestinal stromal tumors, with regard to the number of genetic aberrations found within any one cell. While reductive laboratory studies have supported the potential therapeutic value of inhibitors of these and other signaling pathways in melanoma, even those experiments do not suggest that every cell in a given tumor will be eradicated with agents that target a single pathway. The current generation of clinical trials, which seek to develop novel signal transduction inhibitors, will ultimately provide the building blocks for regimens that take into account the greater complexity of melanoma at the level of aberrant signal transduction.
{"title":"Somatic genetics and targeted therapies for cutaneous melanoma","authors":"Keith Flaherty , Keiran S.M. Smalley","doi":"10.1016/j.uct.2008.06.001","DOIUrl":"10.1016/j.uct.2008.06.001","url":null,"abstract":"<div><p>The standard treatments for metastatic melanoma have not evolved in the past 30 years. It has been a decade since the emergence of high-dose interferon in the adjuvant setting: a therapy with significant limitations in both efficacy and tolerability. The conventional therapies that have proven useful for other cancers have been exhausted with regard to their exploration in melanoma and novel approaches are required. The identification of somatic genetic alterations that activate the MAP kinase and PI3 kinase pathways has provided a foothold for the investigation of signal transduction inhibitors that counter them. Melanoma is more complex than some of the cancers with early success in the application of signal transduction inhibitors, such as chronic phase chronic myelogenous leukemia or gastrointestinal stromal tumors, with regard to the number of genetic aberrations found within any one cell. While reductive laboratory studies have supported the potential therapeutic value of inhibitors of these and other signaling pathways in melanoma, even those experiments do not suggest that every cell in a given tumor will be eradicated with agents that target a single pathway. The current generation of clinical trials, which seek to develop novel signal transduction inhibitors, will ultimately provide the building blocks for regimens that take into account the greater complexity of melanoma at the level of aberrant signal transduction.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2008.06.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55739088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-12-01DOI: 10.1016/S1872-115X(08)00022-4
{"title":"Abbreviations of drugs","authors":"","doi":"10.1016/S1872-115X(08)00022-4","DOIUrl":"https://doi.org/10.1016/S1872-115X(08)00022-4","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(08)00022-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137340786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-03-01DOI: 10.1016/S1872-115X(08)00007-8
{"title":"Copyright","authors":"","doi":"10.1016/S1872-115X(08)00007-8","DOIUrl":"https://doi.org/10.1016/S1872-115X(08)00007-8","url":null,"abstract":"","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1872-115X(08)00007-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137221742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号